Search research articles
Contact Us
Filters
Showing results (71-80 of 89) with videos related to
Page
of 9
Sort By:
The Lancet. Oncology
|
March 5, 2026
Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial
Linde van den Hoek, Mark Burgmans, Thaïs Tong, et al.
Science (New York, N.Y.)
|
September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 24, 2018
An open-label, multicentre safety study of vemurafenib in patients with BRAF<sup>V600</sup>-mutant metastatic melanoma: final analysis and a validated prognostic scoring system
James Larkin, Michael P Brown, Ana M Arance, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2016
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Alexander Martens, Kilian Wistuba-Hamprecht, Marnix Geukes Foppen, et al.
Journal of Translational Medicine
|
July 1, 2021
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy)
Paolo A Ascierto, Christian Blank, Reinhard Dummer, et al.
Nature Medicine
|
September 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
Georgina V Long, Nitya Nair, Daniel Marbach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2016
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide, Alexander Martens, Jessica C Hassel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 23, 2026
Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy
Cato Boreel, Jessie de Ruijter, Olivier van Not, et al.
Journal of Translational Medicine
|
September 7, 2020
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)
Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Journal of Translational Medicine
|
September 4, 2022
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)
Paolo A Ascierto, Sanjiv S Agarwala, Christian Blank, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 89) with videos related to
Sort By:
Page
of 9
The Lancet. Oncology
|
March 5, 2026
Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial
Linde van den Hoek, Mark Burgmans, Thaïs Tong, et al.
Science (New York, N.Y.)
|
September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 24, 2018
An open-label, multicentre safety study of vemurafenib in patients with BRAF<sup>V600</sup>-mutant metastatic melanoma: final analysis and a validated prognostic scoring system
James Larkin, Michael P Brown, Ana M Arance, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2016
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Alexander Martens, Kilian Wistuba-Hamprecht, Marnix Geukes Foppen, et al.
Journal of Translational Medicine
|
July 1, 2021
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy)
Paolo A Ascierto, Christian Blank, Reinhard Dummer, et al.
Nature Medicine
|
September 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
Georgina V Long, Nitya Nair, Daniel Marbach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2016
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide, Alexander Martens, Jessica C Hassel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 23, 2026
Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy
Cato Boreel, Jessie de Ruijter, Olivier van Not, et al.
Journal of Translational Medicine
|
September 7, 2020
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)
Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Journal of Translational Medicine
|
September 4, 2022
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)
Paolo A Ascierto, Sanjiv S Agarwala, Christian Blank, et al.
Page
of 9